Works in Alimentary Pharmacology & Therapeutics, 2024, Vol 60, Issue 11/12


Results: 39
    1
    3
    4
    5
    6
    7
    8
    9
    10

    Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1512, doi. 10.1111/apt.18326
    By:
    • Dulai, Parambir S.;
    • Bonner, Lauren Balmert;
    • Sadler, Charlotte;
    • Raffals, Laura E.;
    • Kochhar, Gursimran;
    • Lindholm, Peter;
    • Buckey, Jay C.;
    • Toups, Gary N.;
    • Rosas, Libeth;
    • Narula, Neeraj;
    • Jairath, Vipul;
    • Honap, Sailish;
    • Peyrin‐Biroulet, Laurent;
    • Sands, Bruce E.;
    • Hanauer, Stephen B.;
    • Scholtens, Denise M.;
    • Siegel, Corey A.;
    • Russ, Kirk B.;
    • Kelly, Matthew P.;
    • Winter, Michael W.
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    23
    24
    25
    26
    27
    28
    29
    30

    The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction‐associated steatotic liver disease and metabolic dysfunction and alcohol‐associated liver disease.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1587, doi. 10.1111/apt.18280
    By:
    • Sogabe, Masahiro;
    • Okahisa, Toshiya;
    • Kagawa, Miwako;
    • Kashihara, Takanori;
    • Shinomiya, Ryo;
    • Miyake, Takanori;
    • Kawaguchi, Tomoyuki;
    • Yokoyama, Reiko;
    • Kagemoto, Kaizo;
    • Kida, Yoshifumi;
    • Okada, Yasuyuki;
    • Tomonari, Tetsu;
    • Kawano, Yutaka;
    • Sato, Yasushi;
    • Nakasono, Masahiko;
    • Takayama, Tetsuji
    Publication type:
    Article
    31
    33
    34
    35

    Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1573, doi. 10.1111/apt.18278
    By:
    • Buti, Maria;
    • Lim, Young‐Suk;
    • Chan, Henry Lik Yuen;
    • Agarwal, Kosh;
    • Marcellin, Patrick;
    • Brunetto, Maurizia R.;
    • Chuang, Wan‐Long;
    • Janssen, Harry L. A.;
    • Fung, Scott K.;
    • Izumi, Namiki;
    • Jablkowski, Maciej S.;
    • Abdurakhmanov, Dzhamal;
    • Abramov, Frida;
    • Wang, Hongyuan;
    • Botros, Irina;
    • Yee, Leland J.;
    • Mateo, Roberto;
    • Flaherty, John F.;
    • Osinusi, Anu;
    • Pan, Calvin Q.
    Publication type:
    Article
    36

    Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1561, doi. 10.1111/apt.18276
    By:
    • Hountondji, Lina;
    • Faure, Stéphanie;
    • Palassin, Pascale;
    • Viel, Philine Witkowski Durand;
    • Dupuy, Marie;
    • Larrey, Dominique;
    • Lamoureux, Anouck;
    • Coustal, Cyrille;
    • Pureur, Dimitri;
    • Lesage, Candice;
    • Assenat, Éric;
    • Rivière, Benjamin;
    • Faillie, Jean‐Luc;
    • Quantin, Xavier;
    • Pageaux, Georges‐Philippe;
    • Maria, Alexandre Thibault Jacques;
    • Meunier, Lucy
    Publication type:
    Article
    37
    38

    Issue Information.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1509, doi. 10.1111/apt.17625
    Publication type:
    Article
    39